Progesterone-induced urticaria: response to buserelin.
We report a 41-year-old Caucasian woman with polycystic liver and kidney disease, and a 9-year history of severe cyclical urticaria related to her menses. The urticaria was not adequately controlled by antihistamines or Prempak-C (conjugated oestrogens and norgestrel). Intradermal testing with progesterone was strongly positive at 30 min and 18 h. Buserelin, administered intranasally at doses of up to 800 micrograms daily, controlled the urticaria within 4 weeks, and she was completely symptom-free thereafter. She had therapy-induced amenorrhoea and occasional hot flushes. Unfortunately, her liver cysts progressively enlarged, and a right hepatectomy was performed in June 1992, but she died after complications 3 weeks later. Prior to this she had been free of urticaria for 6 months after starting buserelin. Buserelin, a gonadotrophin-releasing hormone analogue, may be useful in the management of progesterone-induced urticaria, in patients in whom conjugated oestrogens are contraindicated or unhelpful.
Yee
K C
KC
Department of Dermatology, Leeds General Infirmary, U.K.
Cunliffe
W J
WJ
D000328:Adult; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D002064:Buserelin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008598:Menstruation / Q000502:physiology; D007690:Polycystic Kidney Diseases / Q000150:complications; D011374:Progesterone / Q000502:physiology*; D014581:Urticaria / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
D011374:Progesterone; D002064:Buserelin